You are here: Industry Insights > Epilepsy

News List

New Breakthrough in Epilepsy Drug: First Generic Drug of Eslicarbazepine Will Be Approved Soon PharmaSources/Yi
October 27, 2021
A few days ago, the marketing application (the relevant acceptance No. is CYHS2100147) of type 3 generic drugs "Eslicarbazepine Acetate" submitted by Yangtze River Pharmaceutical Group Beijing Haiyan Pharmaceutical Co., Ltd....
Angelini Pharma’s Ontozry available for patients in Scotland with drug-resistant epilepsy pharmatimes
February 09, 2022
Angelini Pharma’s Ontozry available for patients in Scotland with drug-resistant epilepsy.
Ovid signs license deal with AstraZeneca to expand epilepsy drug pipeline pharmaceutical-business-review
January 04, 2022
ovid Therapeutics has signed a license agreement with AstraZeneca for a library of early-stage small molecules that target the KCC2 transporter.
UK approval for Epidyolex to treat seizures from tuberous sclerosis pharmatimes
August 11, 2021
Jazz Pharmaceuticals subsidiary GW Pharmaceuticals has received approval from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for its cannabidiol Epidyolex as an adjunctive treatment of seizures associated with tuberous sclerosis ...
Global adult epilepsy market to reach $8.35 billion by 2023: GlobalData expresspharma
July 09, 2021
The adult epilepsy market is expected to grow from $5.82 billion in 2020 to $8.35 billion by 2030 across the seven major markets (7MM*) at a compound annual growth rate (CAGR) of 3.7 per cent, according to GlobalData.
Ontozry scores MHRA authorisation for focal-onset seizures pharmatimes
June 18, 2021
The Medicines and Healthcare products Regulatory Agency (MHRA) has granted Arvelle Therapeutics’ Ontozry a marketing authorisation (MA) for the adjunctive treatment of focal-onset seizures, with or without secondary generalisation.
Zydus Cadila gets tentative US FDA approval for Brivaracetam tablets expresspharma
June 16, 2021
Zydus Cadila has received tentative approval from the USFDA to market Brivaracetam Tablets, in the strengths of 10 mg, 25 mg, 50 mg, 75 mg, and 100 mg (US RLD: Briviact Tablets). Brivaracetam is used to treat partial-onset of seizures (epilepsy).
Bright Minds Biosciences Appoints New Board Member and Expands Leadership Team firstwordpharma
June 15, 2021
Bright Minds Biosciences, a biotechnology company focused on developing novel transformative treatments for neuropsychiatry disorders, epilepsy and pain, today announced a new appointment to its Board of Directors and one addition to its leadership team.
Alkem launches Perampil (Perampanel Tablets) expresspharma
June 11, 2021
Alkem has launched Perampil, at 2 mg – Rs 49/strip of 7 tablets, 4 mg – Rs 180/strip of 15 tablets and 6 mg – Rs 300/strip of 15 tablets.
Neonates With Acute Seizures May Be Overmedicated drugs
June 07, 2021
Among neonates with resolution of acute symptomatic seizures, there is no difference in functional neurodevelopment or epilepsy at age 24 months for those discontinuing antiseizure medication (ASM) before hospital discharge versus maintaining medication

Previous page 1 2 3 4 5 6 Next page